
The study revealed that sodium-glucose co-transporter 2 inhibitors (SGLT2i) significantly alleviated cardiomyocyte aging in diabetic cardiomyopathy (DCM) models, improving cardiac function. Using high-fat diet and streptozotocin-induced diabetic mice and AC16 cardiomyocyte models exposed to high glucose and palmitic acid, SGLT2i suppressed ANGPTL4, a senescence-promoting factor identified via RNA sequencing. Furthermore, SGLT2i reduced ANGPTL4 expression by modulating its transcriptional regulator, FOXO1. These findings highlight the FOXO1-ANGPTL4 axis as a therapeutic target for DCM treatment.
Like
Save
Share